Rosalind Advisors, Inc.

In its 13F for Q2 2024 (holdings as of June 30, 2024, filed July 12, 2024), Rosalind Advisors, Inc. reported 35 stock positions worth $126.5 million. Its top holding was Delcath Systems (DCTH) at 12.3% of the portfolio, followed by Myomo (MYO, 6.8%) and Mediwound (MDWD, 6.3%). Compared with Q1 2024, it opened 5 new positions, sold out of 1, added to 13 and reduced 5. The biggest buy was Delcath Systems (DCTH, shares +155%) and the biggest sale Lyra Therapeutics (LYRA, shares −10%).

Most Recent 13F
Q2 2026
Location
TORONTO, A6
CIK
0001622627
Portfolio Value
$126.5M (Q2 2024)
SEC Filing
0001622627-24-000045 ↗ filed Jul 12, 2024

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $106.9M Q1 2024 Q2 2024: $126.5M $126.5M Q2 2024 Q3 2024: $150.7M Q3 2024 Q4 2024: $185.7M Q4 2024 Q1 2025: $205.2M Q1 2025 Q2 2025: $206.6M Q2 2025 Q3 2025: $283.0M Q3 2025 Q4 2025: $274.5M Q4 2025 Q1 2026: $244.1M Q1 2026 Q2 2026: $266.2M Q2 2026

Holdings 35 stocks · $126.5M
DCTH Delcath Systems Inc. 12.28% 2,650,389 $15.5M Add +155.1%
MYO Myomo Inc. 6.76% 2,664,999 $8.6M Add +8.9%
MDWD Mediwound Ltd. 6.30% 513,490 $8.0M Add +5.7%
OPTINOSE INC 6.21% 7,547,148 $7.8M Add +66.2%
ABEO Abeona Therapeutics Inc. 5.87% 1,750,000 $7.4M New
XERS Xeris Biopharma Holdings Inc. 5.55% 3,120,170 $7.0M Add +10.6%
CLRB Cellectar Biosciences Inc. 5.35% 2,705,616 $6.8M Add +335.4%
NSPR Inspiremd Inc. 4.96% 2,513,641 $6.3M Add +266.4%
CYBIN INC 4.14% 19,300,000 $5.2M Add +38.3%
OCUL Ocular Therapeutix Inc. 4.06% 750,000 $5.1M New
ABVX Abivax SA-ADR 3.96% 378,416 $5.0M No change
PROF Profound Medical Corp. 3.54% 533,333 $4.5M No change
CMPS Compass Pathways PLC 3.51% 734,000 $4.4M No change
TRVI Trevi Therapeutics Inc. 3.28% 1,391,577 $4.1M Add +50.3%
KALV Kalvista Pharmaceuticals Inc. 3.15% 337,985 $4.0M Add +17.4%
VRDN Viridian Therapeutics Inc. 3.09% 300,000 $3.9M No change
VRNA Verona Pharma Ltd. 2.86% 250,000 $3.6M No change
CLEARSIDE BIOMEDICAL INC 2.67% 2,592,593 $3.4M No change
OTLK Outlook Therapeutics Inc. 2.63% 450,000 $3.3M Add +44.3%
VERU Veru Inc. 1.79% 2,696,003 $2.3M Reduce -40.1%
PYPD Polypid Ltd. 1.42% 416,800 $1.8M Add +0.2%
RZLT Rezolute Inc. 0.85% 250,000 $1.1M Add +25.0%
KPRX Kiora Pharmaceuticals Inc. 0.85% 255,555 $1.1M Reduce -88.9%
FBIO Fortress Biotech Inc. 0.82% 607,797 $1.0M No change
GERN Geron Corp. 0.67% 200,000 $848K No change
UNICYCIVE THERAPEUTICS INC 0.62% 1,571,200 $787K Reduce -16.4%
SPRB Spruce Biosciences Inc. 0.62% 1,508,419 $781K No change
TLPH Talphera Inc. 0.53% 758,966 $675K No change
DERM Journey Medical Corp. 0.51% 114,132 $644K New
XAIR Beyond Air Inc. 0.38% 903,614 $486K No change
BFRI Biofrontera Inc. 0.36% 504,261 $453K No change
LYRA Lyra Therapeutics Inc. 0.23% 1,034,773 $286K Reduce -9.6%
NAMS Newamsterdam Pharma Co. NV 0.15% 10,123 $194K New
BTAIQ Bioxcel Therapeutics Inc. 0.04% 39,672 $51K New
TNXP Tonix Pharmaceuticals Holdin 0.02% 28,154 $20K Reduce -96.9%

Options reported separately and not counted above: CASSAVA SCIENCES INC puts ($1.3M), XBI puts ($1.0M), ANNOVIS BIO INC puts ($839K), G1 THERAPEUTICS INC puts ($305K), ALNYLAM PHARMACEUTICALS INC puts ($0).

Portfolio Sells Q1 2024 → Q2 2024
LYRA Lyra Therapeutics Inc. Reduce -9.6% 0.23% −6.43
UNICYCIVE THERAPEUTICS INC Reduce -16.4% 0.62% −1.80
TVRD Cara Therapeutics Inc. Sold out 0.00% −1.32
VERU Veru Inc. Reduce -40.1% 1.79% −1.15
KPRX Kiora Pharmaceuticals Inc. Reduce -88.9% 0.85% −0.67
TNXP Tonix Pharmaceuticals Holdin Reduce -96.9% 0.02% −0.14

Portfolio Buys Q1 2024 → Q2 2024
DCTH Delcath Systems Inc. Add +155.1% 12.28% +7.65
ABEO Abeona Therapeutics Inc. New 5.87% +5.87
OCUL Ocular Therapeutix Inc. New 4.06% +4.06
NSPR Inspiremd Inc. Add +266.4% 4.96% +3.44
CLRB Cellectar Biosciences Inc. Add +335.4% 5.35% +3.04
DERM Journey Medical Corp. New 0.51% +0.51
RZLT Rezolute Inc. Add +25.0% 0.85% +0.37
TRVI Trevi Therapeutics Inc. Add +50.3% 3.28% +0.29
NAMS Newamsterdam Pharma Co. NV New 0.15% +0.15
BTAIQ Bioxcel Therapeutics Inc. New 0.04% +0.04
OPTINOSE INC Add +66.2% 6.21% +0.01
KALV Kalvista Pharmaceuticals Inc. Add +17.4% 3.15% −0.05
MDWD Mediwound Ltd. Add +5.7% 6.30% −0.17
XERS Xeris Biopharma Holdings Inc. Add +10.6% 5.55% −0.28
PYPD Polypid Ltd. Add +0.2% 1.42% −0.37
MYO Myomo Inc. Add +8.9% 6.76% −0.72
OTLK Outlook Therapeutics Inc. Add +44.3% 2.63% −0.85
CYBIN INC Add +38.3% 4.14% −1.26

Options Activity Q1 2024 → Q2 2024
CASSAVA SCIENCES INC put New 3,673 $1.3M
XBI SS SPDR S&P Biotech ETF put Reduce -55.2% 22,403 $1.0M
ANNOVIS BIO INC put New 24,154 $839K
G1 THERAPEUTICS INC put New 19,018 $305K
INVESCO QQQ TR put Sold out 100,000 $7Kbefore exit
ALNYLAM PHARMACEUTICALS INC put New 700 $0
AMYLYX PHARMACEUTICALS INC call Sold out 50,000 $0before exit

Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 29$266.2MDCTH, FENC, XERS, SVRA, VSTM
Q1 2026 32$244.1MDCTH, XERS, FENC, SVRA, PCVX
Q4 2025 29$274.5MDCTH, SVRA, FENC, XERS, VRDN
Q3 2025 29$283.0MDCTH, CYTK, FENC, VSTM, RZLT
Q2 2025 29$206.6MDCTH, FENC, CYTK, OCUL, IDYA
Q1 2025 31$205.2MDCTH, VSTM, XERS, MYO, IDYA
Q4 2024Amended 28$185.7MDCTH, MYO, MDWD, CMRX, XERS
Q3 2024 29$150.7MDCTH, MYO, CRMD, ABEO, MDWD
Q2 2024 35$126.5MDCTH, MYO, MDWD, OPTINOSE INC, ABEO
Q1 2024 31$106.9MMYO, LYRA, MDWD, OPTINOSE INC, XERS